Che-chuan Yang

TPQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease - A cross-validation study.

Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease - A cross-validation study.

Journal: Nanomedicine : nanotechnology, biology, and medicine

Published: September 05, 2019

Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease.

Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease.

Journal: Frontiers in neurology

Published: November 21, 2018

Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease.

Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease.

Journal: Journal of Alzheimer's disease : JAD

Published: April 05, 2018

Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

Journal: Frontiers in aging neuroscience

Published: February 21, 2018

Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease.

Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease.

Journal: Journal of Alzheimer's disease : JAD

Published: January 30, 2018

Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases.

Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases.

Journal: Scientific reports

Published: April 04, 2017

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts.

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts.

Journal: Frontiers in aging neuroscience

Published: March 24, 2017

Plasma α-synuclein predicts cognitive decline in Parkinson's disease.

Plasma α-synuclein predicts cognitive decline in Parkinson's disease.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: September 05, 2016

Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles.

Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles.

Journal: Journal of nanobiotechnology

Published: December 22, 2015

A Novel Detection Platform for Shrimp White Spot Syndrome Virus Using an ICP11-Dependent Immunomagnetic Reduction (IMR) Assay.

A Novel Detection Platform for Shrimp White Spot Syndrome Virus Using an ICP11-Dependent Immunomagnetic Reduction (IMR) Assay.

Journal: PloS one

Published: May 18, 2015

Development of antibody functionalized magnetic nanoparticles for the immunoassay of carcinoembryonic antigen: a feasibility study for clinical use.

Development of antibody functionalized magnetic nanoparticles for the immunoassay of carcinoembryonic antigen: a feasibility study for clinical use.

Journal: Journal of nanobiotechnology

Published: August 10, 2014

Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.

Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.

Journal: ACS chemical neuroscience

Published: October 05, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026